In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2 - Aix-Marseille Université Access content directly
Journal Articles Molecules Year : 2020

In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2

Oceane Delandre
  • Function : Author


In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), emerged in Wuhan, China. Despite containment measures, SARS-CoV-2 spread in Asia, Southern Europe, then in America and currently in Africa. Identifying effective antiviral drugs is urgently needed. An efficient approach to drug discovery is to evaluate whether existing approved drugs can be efficient against SARS-CoV-2. Doxycycline, which is a second-generation tetracycline with broad-spectrum antimicrobial, antimalarial and anti-inflammatory activities, showed in vitro activity on Vero E6 cells infected with a clinically isolated SARS-CoV-2 strain (IHUMI-3) with median effective concentration (EC50) of 4.5 +/- 2.9 mu M, compatible with oral uptake and intravenous administrations. Doxycycline interacted both on SARS-CoV-2 entry and in replication after virus entry. Besides its in vitro antiviral activity against SARS-CoV-2, doxycycline has anti-inflammatory effects by decreasing the expression of various pro-inflammatory cytokines and could prevent co-infections and superinfections due to broad-spectrum antimicrobial activity. Therefore, doxycycline could be a potential partner of COVID-19 therapies. However, these results must be taken with caution regarding the potential use in SARS-CoV-2-infected patients: it is difficult to translate in vitro study results to actual clinical treatment in patients. In vivo evaluation in animal experimental models is required to confirm the antiviral effects of doxycycline on SARS-CoV-2 and more trials of high-risk patients with moderate to severe COVID-19 infections must be initiated.
Fichier principal
Vignette du fichier
molecules-25-05064.pdf (872.95 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-03149268 , version 1 (28-06-2023)




Mathieu Gendrot, Julien Andreani, Priscilla Jardot, Sebastien Hutter, Oceane Delandre, et al.. In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2. Molecules, 2020, 25 (21), ⟨10.3390/molecules25215064⟩. ⟨hal-03149268⟩
44 View
4 Download



Gmail Mastodon Facebook X LinkedIn More